Recruiting PHASE2 INTERVENTIONAL 2-arm NCT04787289

A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer

A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer - a Pragmatic Trial

Sponsor: British Columbia Cancer Agency

Conditions Ovarian Cancer Platinum-resistant Ovarian Cancer

Interventions Bevacizumab

Updated 5 times since 2021 Last updated: Aug 6, 2024 Started: Sep 10, 2021 Primary completion: Jan 31, 2025 Completion: Jan 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Ovarian Cancer and Platinum-resistant Ovarian Cancer and is currently actively recruiting participants. British Columbia Cancer Agency leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Aug 2023 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2021 — Aug 2023 [monthly]

Not Yet Recruiting PHASE2
Apr 2021 — Sep 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

British Columbia Cancer Agency

Data source: British Columbia Cancer Agency

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Abbotsford, Canada
• Vancouver, Canada